Amylyx drug beats goal, cuts blood-sugar events 55%
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Amylyx Pharmaceuticals reported Tuesday that its experimental drug reduced serious hypoglycemic events by 55% versus placebo in a Phase 3 trial of patients with post-bariatric hypoglycemia (PBH).
- The Phase 3 study was statistically powered to detect a 35% improvement over placebo; Amylyx's 55% result exceeded that pre-specified benchmark.
- Post-bariatric hypoglycemia causes sudden drops in blood sugar after weight-loss surgery, with serious events classified as medical emergencies that can cause loss of consciousness or seizures, according to the source.
- Justin Klee, Amylyx co-CEO, called the magnitude of the effect "so exciting" and said "any reduction in these hypoglycemic events would be very meaningful for people with PBH and their families."
- The drug, if approved, would become the first treatment specifically for PBH, according to Amylyx — a condition the source describes as having no existing approved therapy.
Why it matters: Amylyx's 55% reduction nearly doubled the 35% statistical benchmark the trial was powered to detect, and because no therapy is approved for post-bariatric hypoglycemia, a positive Phase 3 readout positions the drug as a potential first-in-class treatment for a population that can experience seizure-level emergencies. The result clears Amylyx's main efficacy bar for moving toward an approval filing.
Ask SkimNews
